202 related articles for article (PubMed ID: 31155438)
1. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
DiNatale RG; Sanchez A; Hakimi AA; Reznik E
Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
[TBL] [Abstract][Full Text] [Related]
2. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
4. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
5. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
6. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
7. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
Xiao Y; Meierhofer D
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
[TBL] [Abstract][Full Text] [Related]
8. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
9. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
10. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
11. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
12. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
13. Network-based metabolic characterization of renal cell carcinoma.
Pandey N; Lanke V; Vinod PK
Sci Rep; 2020 Apr; 10(1):5955. PubMed ID: 32249812
[TBL] [Abstract][Full Text] [Related]
14. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
16. The genomics of renal cell carcinoma and its role in renal mass biopsy.
Salami SS; George AK; Udager AM
Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
[TBL] [Abstract][Full Text] [Related]
17. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.
Wang Y; Zhang Y; Wang P; Fu X; Lin W
Mol Cancer; 2020 Oct; 19(1):149. PubMed ID: 33054773
[TBL] [Abstract][Full Text] [Related]
18. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
Weiss RH
Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
[TBL] [Abstract][Full Text] [Related]
19. Introduction to high throughput platforms in kidney cancer: Genomics, transcriptomics, and metabolomics urologic oncology: Seminars and original investigations.
Hakimi AA
Urol Oncol; 2020 Oct; 38(10):741. PubMed ID: 32753358
[No Abstract] [Full Text] [Related]
20. Aerobic glycolysis: a novel target in kidney cancer.
Shuch B; Linehan WM; Srinivasan R
Expert Rev Anticancer Ther; 2013 Jun; 13(6):711-9. PubMed ID: 23773105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
